Literature DB >> 22005189

Inflammation, oxidative stress, and procoagulant and thrombotic activity in adults with obstructive sleep apnea.

.   

Abstract

Obstructive sleep apnea (OSA) is currently considered to be an inflammatory disorder. Evidence suggests that the chronic intermittent hypoxia and, possibly, sleep loss and fragmentation associated with OSA increase the levels of various markers of inflammation, oxidative stress, and procoagulant and thrombotic activity. These alterations may contribute to the development of endothelial and metabolic dysfunction, atherosclerosis and cardiovascular disorders associated with OSA. However, these alterations are also associated with OSA comorbidities, making it difficult to discern which effects are attributable to OSA and/or these other conditions. Well-designed longitudinal and interventional studies that take confounding variables into account are needed to demonstrate a causal link between OSA and inflammation, to assess specific mechanisms that could explain these alterations and to address whether they may be improved by continuous positive airway pressure therapy.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005189     DOI: 10.1159/000325105

Source DB:  PubMed          Journal:  Adv Cardiol        ISSN: 0065-2326


  17 in total

Review 1.  Unexpected benefits of intermittent hypoxia: enhanced respiratory and nonrespiratory motor function.

Authors:  E A Dale; F Ben Mabrouk; G S Mitchell
Journal:  Physiology (Bethesda)       Date:  2014-01

2.  Obstructive sleep apnea and urological comorbidities in males: a population-based study.

Authors:  Shiu-Dong Chung; Shih-Han Hung; Herng-Ching Lin; Ming-Chieh Tsai; Li-Ting Kao
Journal:  Sleep Breath       Date:  2016-04-07       Impact factor: 2.816

Review 3.  [Chronic hypoxia and cardiovascular risk : Clinical significance of different forms of hypoxia].

Authors:  U Koehler; O Hildebrandt; J Krönig; W Grimm; J Otto; W Hildebrandt; R Kinscherf
Journal:  Herz       Date:  2017-05-04       Impact factor: 1.443

4.  Oxidative stress and quality of life in elderly patients with obstructive sleep apnea syndrome: are there differences after six months of Continuous Positive Airway Pressure treatment?

Authors:  Fabiana Yagihara; Ligia Mendonca Lucchesi; Vânia D'Almeida; Marco Túlio de Mello; Sergio Tufik; Lia Rita Azeredo Bittencourt
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

5.  Diabetes Autoantibodies Mediate Neural- and Endothelial Cell- Inhibitory Effects Via 5-Hydroxytryptamine- 2 Receptor Coupled to Phospholipase C/Inositol Triphosphate/Ca2+ Pathway.

Authors:  Mark B Zimering
Journal:  J Endocrinol Diabetes       Date:  2017-10-04

6.  Increased Neuronal Depolarization Evoked by Autoantibodies in Diabetic Obstructive Sleep Apnea: Role for Inflammatory Protease(s) in Generation of Neurotoxic Immunoglobulin Fragment.

Authors:  Mark B Zimering; Zui Pan
Journal:  J Endocrinol Diabetes       Date:  2017-01-22

7.  Toxic Immunoglobulin Light Chain Autoantibodies are Associated with a Cluster of Severe Complications in Older Adult Type 2 Diabetes.

Authors:  Mark B Zimering; N Mirkovic; M Pandya; J H Zimering; J A Behnke; S Thakker-Varia; J Alder; R J Donnelly
Journal:  J Endocrinol Diabetes       Date:  2016-03-08

8.  Cardiovascular and metabolic comorbidities in patients with obstructive sleep apnoea syndrome.

Authors:  M Fusetti; A B Fioretti; M Valenti; F Masedu; M Lauriello; M Pagliarella
Journal:  Acta Otorhinolaryngol Ital       Date:  2012-10       Impact factor: 2.124

9.  Pathogenesis of cognitive dysfunction in patients with obstructive sleep apnea: a hypothesis with emphasis on the nucleus tractus solitarius.

Authors:  Mak Adam Daulatzai
Journal:  Sleep Disord       Date:  2012-01-16

10.  Obstructive sleep apnea and the risk of atopic dermatitis: a population-based case control study.

Authors:  Kai-Jen Tien; Chien-Wen Chou; Shang-Yu Lee; Nai-Cheng Yeh; Chwen-Yi Yang; Feng-Chieh Yen; Jhi-Joung Wang; Shih-Feng Weng
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.